DE602007008124D1 - Piperidin- oder piperazin-substituierte tetrahydronaphthalin-1-carbonsäureverbindungen, die mtp inhibieren - Google Patents

Piperidin- oder piperazin-substituierte tetrahydronaphthalin-1-carbonsäureverbindungen, die mtp inhibieren

Info

Publication number
DE602007008124D1
DE602007008124D1 DE602007008124T DE602007008124T DE602007008124D1 DE 602007008124 D1 DE602007008124 D1 DE 602007008124D1 DE 602007008124 T DE602007008124 T DE 602007008124T DE 602007008124 T DE602007008124 T DE 602007008124T DE 602007008124 D1 DE602007008124 D1 DE 602007008124D1
Authority
DE
Germany
Prior art keywords
tetrahydronaphthalin
piperazine
piperidine
substituted
carboxylic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602007008124T
Other languages
English (en)
Inventor
Lieven Meerpoel
Joannes Theodorus Maria Linders
Libuse Jaroskova
Marcel Viellevoye
Leo Jacobus Jozef Backx
Didier Jean-Claude Berthelot
Guuske Frederike Busscher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of DE602007008124D1 publication Critical patent/DE602007008124D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE602007008124T 2006-10-24 2007-10-22 Piperidin- oder piperazin-substituierte tetrahydronaphthalin-1-carbonsäureverbindungen, die mtp inhibieren Active DE602007008124D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06122817 2006-10-24
PCT/EP2007/061286 WO2008049806A1 (en) 2006-10-24 2007-10-22 Piperidine or piperazine substituted tetrahydro-naphthalene-1-carboxylic acid mtp inhibiting compounds

Publications (1)

Publication Number Publication Date
DE602007008124D1 true DE602007008124D1 (de) 2010-09-09

Family

ID=37885794

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602007008124T Active DE602007008124D1 (de) 2006-10-24 2007-10-22 Piperidin- oder piperazin-substituierte tetrahydronaphthalin-1-carbonsäureverbindungen, die mtp inhibieren

Country Status (28)

Country Link
US (1) US8114880B2 (de)
EP (1) EP2076494B1 (de)
JP (1) JP5506085B2 (de)
KR (1) KR101415536B1 (de)
CN (1) CN101528695B (de)
AR (1) AR063517A1 (de)
AT (1) ATE475648T1 (de)
AU (1) AU2007310925B2 (de)
BR (1) BRPI0717357A2 (de)
CA (1) CA2664141C (de)
CL (1) CL2007003042A1 (de)
CY (1) CY1111010T1 (de)
DE (1) DE602007008124D1 (de)
DK (1) DK2076494T3 (de)
EA (1) EA016311B1 (de)
HK (1) HK1136823A1 (de)
IL (1) IL198332A (de)
JO (1) JO2653B1 (de)
MX (1) MX2009004386A (de)
NO (1) NO20092005L (de)
NZ (1) NZ575615A (de)
PL (1) PL2076494T3 (de)
PT (1) PT2076494E (de)
SI (1) SI2076494T1 (de)
TW (1) TWI396688B (de)
UA (1) UA99109C2 (de)
WO (1) WO2008049806A1 (de)
ZA (1) ZA200902822B (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0211230D0 (en) 2002-05-16 2002-06-26 Medinnova Sf Treatment of heart failure
CN101528671B (zh) 2006-10-24 2013-03-13 詹森药业有限公司 抑制mtp的四氢-萘-1-羧酸衍生物
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
JP5856177B2 (ja) * 2010-10-18 2016-02-09 セレニス セラピューティクス ホールディング エスアー コレステロールモビリゼーションに有用な化合物、組成物及び方法
AU2014249003A1 (en) 2013-03-13 2015-10-15 Forma Therapeutics, Inc. Novel compounds and compositions for inhibition of FASN
DK3484528T3 (da) 2016-07-18 2021-02-15 Janssen Pharmaceutica Nv Tau-pet-billeddannelsesligander
JP6960532B2 (ja) * 2018-05-15 2021-11-05 旭化成株式会社 アミノ酸アミノアルキルエステル又はその無機酸塩の製造方法
TWI767148B (zh) 2018-10-10 2022-06-11 美商弗瑪治療公司 抑制脂肪酸合成酶(fasn)
US10793554B2 (en) 2018-10-29 2020-10-06 Forma Therapeutics, Inc. Solid forms of 4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone
WO2024006701A1 (en) * 2022-06-28 2024-01-04 Stepan Company Method for making dialkyl amino acid ester sulfonates

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595872A (en) 1992-03-06 1997-01-21 Bristol-Myers Squibb Company Nucleic acids encoding microsomal trigyceride transfer protein
US5739135A (en) * 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
EP0832069B1 (de) * 1995-06-07 2003-03-05 Pfizer Inc. Biphenyl-2-carbonsäure-tetrahydro-isochinolin-6-yl amid derivate, deren hestellung und deren verwendung als inhibitoren des mikrosomalen triglycerid-transfer-proteins und/oder der apolipoprotein b (apo b) sekretion
WO1998023593A1 (en) 1996-11-27 1998-06-04 Pfizer Inc. Apo b-secretion/mtp inhibitory amides
GB9826412D0 (en) 1998-12-03 1999-01-27 Glaxo Group Ltd Chemical compounds
DE19963235A1 (de) 1999-12-27 2001-07-05 Boehringer Ingelheim Pharma Substituierte Piperazinderivate, ihre Herstellung und ihre Verwendung als Arzneimittel
GB0013346D0 (en) * 2000-06-01 2000-07-26 Glaxo Group Ltd Therapeutic benzamide derivatives
FR2816940A1 (fr) * 2000-11-23 2002-05-24 Lipha Derives de 4-(biphenylcarbonylamino)-piperidine, compositions les contenant et leur utilisation
CN101528671B (zh) 2006-10-24 2013-03-13 詹森药业有限公司 抑制mtp的四氢-萘-1-羧酸衍生物

Also Published As

Publication number Publication date
IL198332A0 (en) 2010-02-17
PT2076494E (pt) 2010-10-18
US20090325980A1 (en) 2009-12-31
CN101528695B (zh) 2013-07-17
HK1136823A1 (en) 2010-07-09
PL2076494T3 (pl) 2011-01-31
EP2076494A1 (de) 2009-07-08
EA200970398A1 (ru) 2009-08-28
ZA200902822B (en) 2010-07-28
EP2076494B1 (de) 2010-07-28
UA99109C2 (ru) 2012-07-25
CL2007003042A1 (es) 2008-05-02
NZ575615A (en) 2011-01-28
US8114880B2 (en) 2012-02-14
EA016311B1 (ru) 2012-04-30
DK2076494T3 (da) 2010-11-08
AU2007310925A1 (en) 2008-05-02
BRPI0717357A2 (pt) 2013-10-22
TW200833680A (en) 2008-08-16
JP2010507615A (ja) 2010-03-11
JO2653B1 (en) 2012-06-17
IL198332A (en) 2012-08-30
JP5506085B2 (ja) 2014-05-28
AR063517A1 (es) 2009-01-28
SI2076494T1 (sl) 2010-11-30
CY1111010T1 (el) 2015-06-11
AU2007310925B2 (en) 2012-07-26
CA2664141C (en) 2015-04-28
KR101415536B1 (ko) 2014-07-16
ATE475648T1 (de) 2010-08-15
WO2008049806A1 (en) 2008-05-02
KR20090075832A (ko) 2009-07-09
CA2664141A1 (en) 2008-05-02
NO20092005L (no) 2009-06-04
CN101528695A (zh) 2009-09-09
TWI396688B (zh) 2013-05-21
MX2009004386A (es) 2009-05-08

Similar Documents

Publication Publication Date Title
DE602007008124D1 (de) Piperidin- oder piperazin-substituierte tetrahydronaphthalin-1-carbonsäureverbindungen, die mtp inhibieren
FI20060727A0 (fi) Hissijärjestelmä
FI20060588A0 (fi) Hissijärjestelmä
FI20060511A0 (fi) Hissijärjestelmä
FI20060214A0 (fi) Hissijärjestelmä
DK2049671T3 (da) Regulatoriske nukleinsyreelementer
ATE510923T1 (de) Nukleinsäure
FI20060409A (fi) Hissijärjestelmä
DE602007001681D1 (de) 1,3-dioxan-carboxylsäuren
FI20060963A (fi) Hissijärjestelmä
FI20061050A0 (fi) Hissijärjestelmä
IT1394881B1 (it) Apparecchio di controllo di posizione.
BRPI0716197A2 (pt) Fungicidas
DE502007002429D1 (de) Endreaktor
DK1996027T3 (da) Harpiksindkapslet næringsmiddelsyre
FI20060825A (fi) Hissijärjestelmä
DE602007010931D1 (de) Säurefarbstoffe
DE112007003253A5 (de) Identifikationssystem
DE602007001604D1 (de) Säurefarbstoffe
FR2901630B1 (fr) Passe-barre
FI20060469A0 (fi) Hissijärjestelmä
ITRM20060484A1 (it) Liquore di pinoli
UA14090S (uk) Завершувальна планка
ITCA20060010A1 (it) Spiedatore per anguille o capitoni.
ITRM20060485A1 (it) Liquore di caramello